Lantern Pharma wins USPTO notice of allowance for LP-284 blood cancer treatment patent application

Bitget2026/09/22 11:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Lantern Pharma received a USPTO Notice of Allowance for a method-of-treatment patent covering LP-284 in mantle cell lymphoma, double-hit lymphoma.
Claims include LP-284 as monotherapy or in combinations with other anti-cancer agents, with intravenous or intraperitoneal administration covered.
Once issued, the patent is expected to extend LP-284 protection into 2042, adding to composition-of-matter coverage into 2039.
LP-284 is in a Phase 1a dose-escalation trial in relapsed or refractory B-cell non-Hodgkin’s lymphomas, solid tumors.
Lantern cited a $4 billion annual global market opportunity for targeted blood cancers, estimating 40,000 to 80,000 patients annually.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260922872386) on September 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lantern Pharma wins USPTO notice of allowance for LP-284 blood cancer treatment patent application

You may also like

Crypto prices